Production (Stage)
SpringWorks Therapeutics, Inc.
SWTX
$46.48
$0.210.45%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 200.12M | 172.04M | 115.94M | 66.64M | 26.45M |
| Total Other Revenue | 19.55M | 19.55M | 19.55M | 19.55M | -- |
| Total Revenue | 219.67M | 191.59M | 135.49M | 86.19M | 26.45M |
| Cost of Revenue | 14.88M | 12.55M | 7.42M | 4.08M | 1.62M |
| Gross Profit | 204.80M | 179.04M | 128.07M | 82.11M | 24.83M |
| SG&A Expenses | 273.04M | 256.65M | 239.39M | 224.33M | 213.49M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 484.41M | 469.72M | 430.74M | 407.50M | 385.70M |
| Operating Income | -264.74M | -278.13M | -295.25M | -321.31M | -359.25M |
| Income Before Tax | -253.93M | -258.13M | -275.16M | -301.06M | -339.07M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -253.93 | -258.13 | -275.16 | -301.06 | -339.07 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -253.93M | -258.13M | -275.16M | -301.06M | -339.07M |
| EBIT | -264.74M | -278.13M | -295.25M | -321.31M | -359.25M |
| EBITDA | -260.90M | -274.66M | -292.26M | -318.71M | -357.10M |
| EPS Basic | -3.41 | -3.48 | -3.89 | -4.44 | -5.15 |
| Normalized Basic EPS | -2.13 | -2.18 | -2.43 | -2.77 | -3.22 |
| EPS Diluted | -3.41 | -3.48 | -3.89 | -4.44 | -5.15 |
| Normalized Diluted EPS | -2.13 | -2.18 | -2.43 | -2.77 | -3.22 |
| Average Basic Shares Outstanding | 297.65M | 296.53M | 287.49M | 275.75M | 264.09M |
| Average Diluted Shares Outstanding | 297.65M | 296.53M | 287.49M | 275.75M | 264.09M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |